Johnson LB - Search Results

1

Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis.

Kale-Pradhan PB, Morgan G, Wilhelm SM, Johnson LB. Kale-Pradhan PB, et al. Among authors: johnson lb. Pharmacotherapy. 2010 Dec;30(12):1207-13. doi: 10.1592/phco.30.12.1207. Pharmacotherapy. 2010. PMID: 21114387

2

Treatment and recurrence management of staphylococcal infections: community-acquired MRSA.

Kale-Pradhan P, Johnson LB. Kale-Pradhan P, et al. Among authors: johnson lb. Expert Rev Anti Infect Ther. 2008 Dec;6(6):909-15. doi: 10.1586/14787210.6.6.909. Expert Rev Anti Infect Ther. 2008. PMID: 19053903 Review.

3

Early response of ceftaroline fosamic in the treatment of soft-tissue infections.

Giuliano C, Kale-Pradhan PB, Johnson LB. Giuliano C, et al. Among authors: johnson lb. Expert Rev Clin Pharmacol. 2012 Sep;5(5):509-12. doi: 10.1586/ecp.12.50. Expert Rev Clin Pharmacol. 2012. PMID: 23121271

4

Meta-Analysis: Vancomycin Treatment Failures for MRSA Bacteremia Based on MIC Determined by E-test.

Kale-Pradhan PB, Mariani NP, Wilhelm SM, Johnson LB. Kale-Pradhan PB, et al. Among authors: johnson lb. J Pharm Technol. 2016 Apr;32(2):65-70. doi: 10.1177/8755122515610125. Epub 2015 Oct 9. J Pharm Technol. 2016. PMID: 34860997 Free PMC article.

5

Clinical Outcomes of Zinc Supplementation Among COVID-19 Patients.

Berti AD, Kale-Pradhan PB, Giuliano CA, Aprilliano BN, Miller CR, Alyashae BT, Bhargava A, Johnson LB. Berti AD, et al. Among authors: johnson lb. Curr Drug Saf. 2022;17(4):366-369. doi: 10.2174/1574886317666220317115023. Curr Drug Saf. 2022. PMID: 35301954

6

Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD.

Baalbaki N, Giuliano C, Hartner CL, Kale-Pradhan P, Johnson L. Baalbaki N, et al. J Gen Intern Med. 2022 Dec;37(16):4183-4188. doi: 10.1007/s11606-022-07486-5. Epub 2022 Mar 22. J Gen Intern Med. 2022. PMID: 35316516 Free PMC article.

7

Biomarkers in the intensive care setting: A focus on using procalcitonin and C-reactive protein to optimize antimicrobial duration of therapy.

August BA, Kale-Pradhan PB, Giuliano C, Johnson LB. August BA, et al. Among authors: johnson lb. Pharmacotherapy. 2023 Sep;43(9):935-949. doi: 10.1002/phar.2834. Epub 2023 Jun 24. Pharmacotherapy. 2023. PMID: 37300522 Review.

8

Second-generation azole antifungal agents.

Kale P, Johnson LB. Kale P, et al. Among authors: johnson lb. Drugs Today (Barc). 2005 Feb;41(2):91-105. doi: 10.1358/dot.2005.41.2.882661. Drugs Today (Barc). 2005. PMID: 15821782 Review.

9

Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.

Johnson LB, Saravolatz LD. Johnson LB, et al. Clin Infect Dis. 2009 Apr 15;48(8):1123-8. doi: 10.1086/597469. Clin Infect Dis. 2009. PMID: 19275497 Review.

10

Voriconazole: a new triazole antifungal agent.

Johnson LB, Kauffman CA. Johnson LB, et al. Clin Infect Dis. 2003 Mar 1;36(5):630-7. doi: 10.1086/367933. Epub 2003 Feb 10. Clin Infect Dis. 2003. PMID: 12594645 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

383 results

Search Page

Filters